Endothelial-released CD93 mediates podocyte activation in minimal change disease
Sunday, April 24, 2022
4:15 PM – 4:30 PM US MT
Location: Convention Center: 708/710/712
CE: Enduring CME: 0.25
Publication Number: 2615.4
Federica Piani, University of Bologna, Bologna, Emilia-Romagna, Italy; Colin D. Bauer, University of Colorado School of Medicine, WESTMINSTER, CO, United States; mindy banks, rocky mountain pediatric kidney center, denver, CO, United States; Carmen de Lucas-Collantes, Servicio Madrileño de Salud, Madrid, Madrid, Spain; Flor A. Ordóñez, Division of Pediatric Nephrology. Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Eric Schmidt, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States; Miguel Lanaspa, Oregon Health & Science University School of Medicine, Portland, OR, United States; Ana Andres-hernando, Oregon Health & Science University School of Medicine, Portland, OR, United States; Simon C. Satchell, University of Bristol, Bristol, England, United Kingdom; Petter Bjornstad, Children's Hospital Colorado, Aurora, CO, United States; Scott Lucia, University of Colorado School of Medicine, Aurora, CO, United States; Yuwen Zhu, University of Colorado School of Medicine, Aurora, CO, United States; Judith Blaine, University of Colorado School of Medicine, Aurora, CO, United States; Joshua thurman, University of Colorado School of Medicine, Aurora, CO, United States; Richard Johnson, University of Colorado School of Medicine, Aurora, CO, United States; Gabriel Cara-Fuentes, University of Colorado School of Medicine, Denver, CO, United States
Presenting Author(s)
Gabriel Cara-Fuentes, MD, PhD
Assistant Professor University of Colorado School of Medicine Denver, Colorado, United States
Participants should be aware of the following financial/non-financial relationships:
Gabriel Cara-Fuentes, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Federica Piani, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Colin D. Bauer, Bauer, BA's in Chemistry and Biochemistry: I do not have any relevant financial / non-financial relationships with any proprietary interests.
mindy banks, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Carmen de Lucas-Collantes, MD. Ph.D: ● Alexion (Currently Ongoing) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness). ● Kyowa Kyrin (Currently Ongoing) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness).
Flor A. Ordóñez, M.D.: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Eric Schmidt, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Miguel Lanaspa, DVM PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Ana Andres-hernando, DVM, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Simon C. Satchell, Satchell, MB BS, PhD: ● Ferring Pharmaceuticals (Ended In the Past 24 Months) (Products/Services: Research Support including clinical trials & the principal or named investigator). ● Novo Nordisk (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant). ● UCB Pharma (Ended In the Past 24 Months) (Products/Services: Research Support including clinical trials & the principal or named investigator).
Petter Bjornstad, MD: ● AstraZeneca (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Advisory Committee). ● Bayer (Currently Ongoing) (Products/Services: Consultant, Advisory Committee). ● Boehringer-Ingelheim (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Advisory Committee). ● Bristol-Meyer-Squibb (Ended In the Past 24 Months) (Products/Services: Consultant). ● Horizon Pharma (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Advisory Committee). ● Lilly (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Advisory Committee). ● Novo Nordisk (Currently Ongoing) (Products/Services: Consultant, Advisory Committee). ● XORTX (Ended In the Past 24 Months) (Products/Services: Advisory Committee).
Scott Lucia, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Yuwen Zhu, PhD: ● Dynamicure Biotechnology (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant, Intellectual Property including patent beneficiary and royalties).
Judith Blaine, MD,PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Joshua thurman, MD: ● Alexion Pharmaceuticals (Currently Ongoing) (Products/Services: Intellectual Property including patent beneficiary and royalties). ● Q32 Bio (Currently Ongoing) (Products/Services: Consultant, Intellectual Property including patent beneficiary and royalties, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).
Richard Johnson, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
